Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400223 | 0.76 | — | — | |
| SCHEMBL2071440 | 0.71 | — | — | |
| SCHEMBL450139 | 0.71 | — | — | |
| SCHEMBL30828773 | 0.71 | — | — | |
| SCHEMBL17800230 | 0.71 | ADRA2A (0.32) | ADRA2AADRA2BADRA2CNUDT1 | |
| SCHEMBL2161648 | 0.69 | PNMT (0.34) | ADRA2AADRA2BADRA2CCYP1A2SMN1; SMN2 | |
| SCHEMBL3939163 | 0.68 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CCYP1A2SMN1; SMN2 | |
| SCHEMBL30806877 | 0.68 | CD44 (0.42) | ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL325377 | 0.68 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CNUDT1CYP1A2 | |
| SCHEMBL19293287 | 0.68 | NPC1 (0.33) | ADRA2AADRA2BADRA2CCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013797-B1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-01-03 | — | — | EP | claimed |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2016-06-09 | — | — | US | claimed |
| EP-3013797-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2016-05-04 | — | — | EP | claimed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | claimed |
| EP-2424858-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-14 | — | — | EP | claimed |
| EP-2424858-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | claimed |
| WO-2010126851-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | claimed |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | claimed |
| EP-3013797-B1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-01-03 | — | — | EP | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2016-06-09 | — | — | US | disclosed |
| EP-3013797-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| EP-2424858-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-14 | — | — | EP | disclosed |
| US-8362249-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| EP-2424858-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126851-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BRAF, EGFR, ERBB2 | ADRA2A 4589/4885ADRA2B 4687/4885ADRA2C 4459/4885 |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | ADRA2A 281/4885ADRA2B 197/4885ADRA2C 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.